CCL28: A Potential Drug Target and Biomarker for the Treatment of Cancer

Target Name: CCL28

NCBI ID: G56477

CCL28

CCL28: A Potential Drug Target and Biomarker for the Treatment of Cancer

Abstract:

CCK1 (Cytokine-Induced Killing 1), also known as CCL28, is a protein that has been identified as a potential drug target and biomarker for the treatment of cancer. It is a cytokine that is expressed in various tissues, including the immune system, and has been shown to have both pro-inflammatory and anti-inflammatory effects. The purpose of this article is to review the current research on CCL28 and its potential as a drug target and biomarker for cancer.

Introduction:

Cancer is a leading cause of death worldwide, and there is a high demand for effective treatments that can provide sustainable remission. The development of new drugs that target specific proteins has become a significant area of research in the field of cancer treatment. One of the proteins that has gained significant attention in recent years is CCL28. CCL28 is a cytokine that is expressed in various tissues and has been shown to have both pro-inflammatory and anti-inflammatory effects. The potential of CCL28 as a drug target and biomarker for cancer treatment makes it an attractive subject of research.

Current Research on CCL28:

The study of CCL28 has been ongoing for several years, and several studies have demonstrated its potential as a drug target and biomarker for cancer. One of the most significant findings is the evidence of CCL28's role in cancer progression. Several studies have shown that high levels of CCL28 were associated with poor prognosis in cancer patients. Additionally, the use of inhibitors that target CCL28 has been shown to improve the efficacy of cancer treatments.

Another area of research related to CCL28 is its potential as a biomarker for cancer. Several studies have shown that the levels of CCL28 can be used as a diagnostic marker for cancer. For example, one study showed that CCL28 levels were significantly elevated in the blood samples of patients with breast cancer compared to those without the disease. Additionally, several studies have shown that the levels of CCL28 have been used as a marker for the evaluation of cancer-related tissues, such as the tumor microenvironment.

Despite the promising findings, more research is needed to fully understand the potential of CCL28 as a drug target and biomarker for cancer. Further studies are needed to determine the optimal conditions for the use of CCL28 as a drug, as well as to explore its potential as a biomarker for cancer.

Conclusion:

In conclusion, CCL28 is a protein that has gained significant attention in recent years due to its potential as a drug target and biomarker for cancer. The current research has shown that CCL28 is involved in cancer progression and has been associated with poor prognosis in cancer patients. Additionally, several studies have shown that CCL28 can be used as a biomarker for cancer, making it an attractive subject of research. Further studies are needed to fully understand the potential of CCL28 as a drug target and biomarker for cancer, and to explore its potential in the treatment of cancer.

Protein Name: C-C Motif Chemokine Ligand 28

Functions: Chemotactic activity for resting CD4, CD8 T-cells and eosinophils. Binds to CCR3 and CCR10 and induces calcium mobilization in a dose-dependent manner

The "CCL28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets